跳转至内容
Merck

T2807

Sigma-Aldrich

胸苷磷酸化酶,重组 来源于大肠杆菌

recombinant, expressed in E. coli, buffered aqueous solution, ≥500 units/mL

别名:

胸苷:正磷酸脱氧-D-核糖基转移酶

登录查看公司和协议定价


About This Item

CAS号:
MDL號碼:
分類程式碼代碼:
12352204
NACRES:
NA.54

重組細胞

expressed in E. coli

品質等級

形狀

buffered aqueous solution

濃度

≥500 units/mL

UniProt登錄號

儲存溫度

2-8°C

基因資訊

Escherichia coli K12 ... deoA(948901)

正在寻找类似产品? 访问 产品对比指南

一般說明

胸苷磷酸化酶抑制血管平滑肌细胞增殖。

應用

胸苷磷酸化酶已用于评估TAS-102治疗晚期实体瘤患者的研究。 胸苷磷酸化酶也已用于研究FP3蛋白对原发性结肠癌患者来源的肿瘤组织异种移植模型的抗肿瘤作用。

生化/生理作用

一种对胸腺嘧啶可逆性转化为胸腺嘧啶进行催化的酶。胸苷磷酸化酶是嘧啶核苷挽救途径的一部分。该途径允许嘧啶碱基被回收用于核苷酸生物合成,而1-磷酸戊糖被转化为磷酸戊糖分流和糖酵解的中间体。 大肠埃希菌胸苷磷酸化酶与人序列具有40%的序列同源性,已发现该序列与血管生成剂血小板衍生的内皮生长因子相同。 在鸡绒膜尿囊膜测定中,纯化的大肠埃希菌酶已显示出刺激血管生长的作用。

單位定義

一个单位将在25℃的pH 7.4下每分钟将1.0 μmole的胸苷和磷酸盐分别转化为胸腺嘧啶和2-脱氧核糖1-磷酸。

外觀

溶于含2 mM尿嘧啶、0.02%叠氮化钠和牛血清白蛋白的0.5 M磷酸钾溶液

準備報告

大肠埃希菌克隆并在过表达大肠埃希菌中产生

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

T Doi et al.
British journal of cancer, 107(3), 429-434 (2012-06-28)
TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a dose-escalation phase I study in Japanese patients with advanced solid tumours. TAS-102 was administered twice daily on days 1-5 and days 8-12 in
Charlotte Gasson et al.
Journal of pharmaceutical and biomedical analysis, 72, 16-24 (2012-11-14)
Erythrocyte encapsulated thymidine phosphorylase (EE-TP) is under development as an enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a fatal metabolic disorder resulting from an inherited deficiency of the enzyme thymidine phosphorylase. We report here the development and validation of
Jian Zhang et al.
Cancer chemotherapy and pharmacology, 71(1), 103-113 (2012-10-12)
The difference between combinational and pre-planned sequential therapies using regimens that include non-anthracycline and taxane in the first-line setting remains unclear. The purpose of this study is to explore the interaction between vinorelbine (N) and capecitabine (X) in breast cancer
Domenico Ribatti et al.
Expert opinion on therapeutic targets, 16(12), 1215-1225 (2012-09-18)
Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help
Hong-Yun Zhao et al.
Anti-cancer drugs, 23(5), 534-542 (2012-04-07)
The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy. We evaluated the clinicopathological/prognostic significance of thymidylate synthase

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门